Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B1TI
|
|||
| Former ID |
DNCL003541
|
|||
| Drug Name |
MPSK3169A
|
|||
| Synonyms |
RG7652
Click to Show/Hide
|
|||
| Indication | Cardiovascular disease [ICD-11: BA00-BE2Z; ICD-10: I00-I99] | Phase 2 | [1] | |
| Metabolic disorder [ICD-11: 5C50-5D2Z; ICD-10: E70-E90; ICD-9: 270-279] | Phase 1 | [2] | ||
| Company |
Genentech
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | PCSK9 messenger RNA (PCSK9 mRNA) | Target Info | Modulator | [3] |
| WikiPathways | PCSK9-mediated LDLR degradation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01609140) A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease. U.S. National Institutes of Health. | |||
| REF 2 | GW24-e2907 ffects of RG7652, a fully human mAb against proprotein convertase subtilisin/kexin type 9, on LDL-c: a Phase I, randomised, double-blind, placebo-controlled, single- and multiple-dose study. Heart 2013;99:A153. | |||
| REF 3 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2388). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.